Location: Cambridge MA
Cambridge, MA-based H3 Biomedicine (http://www-dev.h3biomedicine.com/) is a leading company in cancer genomics driven drug discovery, delivering on the promise of precision medicine. The company was launched in 2011 with an unprecedented $200 million in initial funding from Eisai, plus a continued ongoing commitment to fund H3’s robust discovery pipeline and clinical programs. Now with three clinical stage anti-cancer molecules in active development, H3 is able to uniquely leverage distinct insights from cancer genomics and real-life patient data to advance its projects to clinical proof of concept and beyond. H3 embraces a novel business model in which it collaborates with Eisai, a leading global pharmaceutical company, to create a prolific drug discovery engine and partnership platform.
H3 Biomedicine Inc. [H3B] is searching for a dynamic Summer Intern to join our growing Biology team. The Intern will be supporting the mechanistic studies of a new target in our oncology programs. The successful candidate will have the chance to interact and collaborate cross-functionally with scientists in different departments including biology, chemistry, and biochemistry. This is a great opportunity for an undergraduate biology major looking to gain experience in an oncology setting and who wants to work in precision medicine. As a member of the Discovery Biology team, he/she will contribute to the series of experiments for in vitro assays and will also have the chance to participate in team meetings and observe the drug discovery process. The applicant is expected to possess excellent communication skills, a genuine eagerness to learn and a proven ability to work well in teams.
H3 is a place where you can create great relationships, gain mentors, and enjoy a fast-paced highly collaborative environment to advance your career to the next level. Enjoy perks like free lunch and snacks every day including fresh fruit; wellness programs; massage; opportunities to volunteer; happy hours; holiday parties; paid holidays plus week-long winter shutdown; and subsidized parking or public transportation reimbursement. H3 internships offer meaningful experiences as well as endless options for learning and growth.
Principal Duties and Responsibilities
- Conduct molecular biology, cell biology, and biochemistry experiments to support the mechanistic studies of our ongoing oncology project
- Perform cell-based assays to assess the impact of small molecule inhibitors on cancer cell proliferation and/or differentiation
- Design, document and analyze experiments; maintain good written records of laboratory procedures, results and conclusions
- Utilize contemporary immuno-oncology principles and technologies in the proposal and execution of experiments.
- Perform literature searches and follow current literature in support of research.
- Present the result as a poster at the end of the internship
- College senior students or graduate students majoring in molecular biology, cell biology, biochemistry, or similar fields
- Basic understanding of molecular biology, cell biology or oncology. Must have taken general biology, molecular biology or similar courses
- Familiarity and experience with basic laboratory techniques in molecular biology, cell biology or biochemistry. (Including pipetting, PCR, cell culture, Western Blotting etc.)
- Demonstrate scientific engagement and motivation; willing to learn new techniques and ask questions
- Excellent organizational and communication skills; ability to solve problems and multitask
- Experience in cancer biology, a biopharma setting or a molecular biology lab
About H3 Biomedicine Inc.
H3 Biomedicine Inc. is a privately-held, uniquely-structured oncology discovery enterprise whose sole mission is to become a prolific source of new drugs that treat more human cancers with greater success. H3 Biomedicine is applying the expertise of leading scientists to the integration of insights from cancer genomics with innovative capabilities in synthetic chemistry and tumor biology to pursue the most promising current opportunity in cancer therapeutics: patient-based, genomics-driven, small molecule drugs.Submit Your Résumé